首页> 美国卫生研究院文献>Hematology Reports >An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment
【2h】

An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment

机译:一例非典型溶血性尿毒症综合征伴后可逆性脑病综合征的成人病例:对迟发性依库丽单抗治疗的成功反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Atypical hemolytic uremic syndrome is a rare and progressive disease caused by uncontrolled alternative complement activation. Dysregulatıon of the complement activation results in thrombotic microangiopathy and multiorgan damage. A 29-yearold woman who was admitted with complaints of vomiting and headache was detected to have acute renal failure with microangiopathic hemolytic anemia (MAHA). After the diagnosis of atypical hemolytic uremic syndrome (aHUS), she was treated with plasma exchange (PE) and hemodialysis (HD). She has experienced hypertensionrelated posterior reversible encephalopathy syndrome (PRES) at the second plasma exchange. She was initiated on eculizumab therapy because of no response to PE on the 34th days. Her renal functions progressively improved with eculizumab treatment. Dependence on dialysis was over by the 4th month. Dialysis free-serum Creatinine level was 2.2 mg/dL [glomerular filtration rate (e-GFR): 30 mL/min/1.73 m2] after 24 months.Neurological involvement (PRES, etc.) is the most common extrarenal complication and a major cause of mortality and morbidity from aHUS. More importantly, we showed that renal recovery may be obtained following late-onset eculizumab treatment in patient with aHUS after a long dependence on hemodialysis.
机译:非典型溶血性尿毒症综合征是由不受控制的替代性补体激活引起的罕见和进行性疾病。补体激活的调节异常导致血栓性微血管病和多器官损伤。一名因呕吐和头痛而入院的29岁妇女被发现患有急性肾功能衰竭,并伴有微血管性溶血性贫血(MAHA)。在诊断出非典型溶血性尿毒症综合征(aHUS)之后,她接受了血浆置换(PE)和血液透析(HD)治疗。在第二次血浆置换时,她经历了高血压相关的后可逆性脑病综合征(PRES)。由于第34天对PE没有反应,因此开始使用依库丽单抗治疗。依库丽单抗治疗使她的肾功能逐渐改善。对透析的依赖在第4个月结束。 24个月后透析游离血清肌酐水平为2.2 mg / dL [肾小球滤过率(e-GFR):30 mL / min / 1.73 m 2 ]。神经学受累(PRES等)为最常见的肾外并发症,是aHUS致死和发病的主要原因。更重要的是,我们显示长期依赖血液透析后,aHUS患者使用迟发型依库丽单抗治疗后可实现肾脏恢复。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号